Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifaximin for Travelers' Diarrhea Prophylaxis in Military Personnel
NCT02498301Completed
- Sponsor
- Henry M. Jackson Foundation for the Advancement of Military Medicine
- Start
- Nov 2015
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Randomised, double-blind trial of rifaximin in traveler's diarrhea (TD) (3 arms), sponsored by Henry M. Jackson Foundation for the Advancement of Military Medicine. Primary endpoint: Risk of travelers diarrhea during chemoprophylaxis up to 6 weeks. Started Nov 2015; status: completed.
02
Drugs
rifaximin
03
Conditions
traveler's diarrhea (TD)
Beyond the preview
Go deeper on NCT02498301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02498301.